
    
      A single-site, prospective, observational clinical study of Cytal® Wound Matrix alone or in
      combination with MicroMatrix® for the management of wounds. Up to 100 patients with multiple
      wound types including but not limited to, venous ulcers, diabetic foot ulcers, trauma wounds,
      and external surgical wounds will be treated either with Cytal® Wound Matrix alone or with
      Cytal® Wound Matrix and MicroMatrix® for wounds exceeding 3mm in depth. Wound healing
      efficacy, effect of treatment on patient-reported quality of life, complete wound management,
      wound-related adverse event, and wound pathology will be measured. The protocol defined
      patient follow-up is 12 months.
    
  